Safety and Bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular Degeneration
Public ClinicalTrials.gov record NCT04746963. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 1/2a Study of the Safety and Bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular Degeneration (nAMD)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is an open-label, dose-escalating, 48-week study assessing the safety, tolerability, bioactivity and duration of action of a single intravitreal injection of 0.1 mg, 0.25 mg, or 0.5 mg AXT107 in approximately 18 subjects (up to 6 subjects per dose) with nAMD.
Study identification
- NCT ID
- NCT04746963
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 3 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 50 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 1, 2021 (Actual)
- Primary completion
- Oct 1, 2022 (Actual)
- Completion
- Oct 1, 2022 (Actual)
- Last update posted
- Mar 22, 2024
2021 – 2022
United States locations
- U.S. sites
- 10
- U.S. states
- 8
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| AsclepiX Investigative Site | Gilbert | Arizona | 85053 | — |
| AsclepiX Investigative Site | Los Angeles | California | 90211 | — |
| AsclepiX Investigative Site | St. Petersburg | Florida | 33711 | — |
| AsclepiX Investigative Site | Boston | Massachusetts | 02114 | — |
| AsclepiX Investigative Site | Reno | Nevada | 89502 | — |
| AsclepiX Investigative Site | Eugene | Oregon | 97401 | — |
| AsclepiX Investigative Site | Huntingdon Valley | Pennsylvania | 19006 | — |
| AsclepiX Investigative Site | Abilene | Texas | 79606 | — |
| AsclepiX Investigative Site | McAllen | Texas | 78503 | — |
| AsclepiX Investigative Site | The Woodlands | Texas | 77384 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04746963, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 22, 2024 · Synced Oct 30, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04746963 live on ClinicalTrials.gov.